As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.
8 Analysts have issued a Virios Therapeutics Inc forecast:
8 Analysts have issued a Virios Therapeutics Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -18 -18 |
-
|
EBIT (Operating Income) EBIT | -18 -18 |
234%
234%
|
Net Profit | -27 -27 |
400%
400%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.
Head office | United States |
CEO | Gregory Duncan |
Founded | 2012 |
Website | dwtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.